Amgen’s New Study on AMG 193: A Potential Game-Changer for Thoracic Tumors

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.

Amgen Inc. has launched a Phase 1b clinical study titled ‘AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AMG 193, a PRMT5 inhibitor, alone or in combination with other therapies in patients with advanced thoracic tumors. This study is significant as it targets MTAP-deleted tumors, which are challenging to treat, potentially offering new therapeutic options.

The interventions being tested include AMG 193, administered orally, and other drugs like Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, and Sotorasib, administered intravenously or orally. These combinations aim to determine the maximum tolerated dose and safety profile of AMG 193 in various subgroups of patients with non-small cell lung cancer (NSCLC).

The study is designed as a non-randomized, parallel assignment with no masking, focusing primarily on treatment. This straightforward design allows for a clear assessment of AMG 193’s effects in combination with other therapies.

The study began on September 17, 2024, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 24, 2025, indicating ongoing progress in the recruitment phase.

This clinical update could positively impact Amgen’s stock performance by showcasing its commitment to innovative cancer therapies. The study’s focus on MTAP-deleted tumors positions Amgen at the forefront of targeted cancer treatment, potentially enhancing investor sentiment. Competitors in the oncology space will likely monitor these developments closely.

The study is currently recruiting, with further details available on the ClinicalTrials portal.